SCHEMBL16509282

SCHEMBL16509282

CCC(=O)NC[C@@H]1CCCCN1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FDPS P14324 2/20 0.44
MTNR1A P48039 1/20 0.43
DRD2 P14416 2/20 0.40
DRD3 P35462 2/20 0.40
SCN9A Q15858 1/20 0.40
CYP2D6 P10635 4/20 0.40
LMNA P02545 4/20 0.40
CYP1A2 P05177 3/20 0.40
TSHR P16473 2/20 0.40
SLC6A2 P23975 2/20 0.40
KCNH2 Q12809 2/20 0.40
MEN1 O00255 2/20 0.40
TP53 P04637 2/20 0.40
KMT2A Q03164 2/20 0.40
ALDH1A1 P00352 1/20 0.40
MLNR O43193 1/20 0.40
ABCB11 O95342 1/20 0.40
EGFR P00533 1/20 0.40
FYN P06241 1/20 0.40
CHRM2 P08172 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15244822 1.00 FDPS (0.44) FDPSMTNR1ADRD2DRD3SCN9A
SCHEMBL16509288 0.95 MTNR1A (0.44) FDPSMTNR1ADRD2DRD3MEN1
SCHEMBL12507083 0.95 MTNR1A (0.44) FDPSMTNR1ADRD2DRD3MEN1
SCHEMBL22578312 0.87 FDPS (0.41) FDPSDRD2DRD3SCN9ACYP2D6
SCHEMBL13186048 0.82 FDPS (0.46) FDPSDRD2DRD3SCN9ACYP2D6
SCHEMBL13207251 0.82 FDPS (0.46) FDPSDRD2DRD3SCN9ACYP2D6
SCHEMBL12506228 0.82 FDPS (0.46) FDPSDRD2DRD3SCN9ACYP2D6
SCHEMBL5167742 0.81 PRCP (0.45) FDPSMTNR1ADRD2DRD3LMNA
SCHEMBL20186812 0.80 FDPS (0.47) FDPSSCN9ACYP2D6LMNACYP1A2
SCHEMBL3088560 0.80 FDPS (0.47) FDPSSCN9ACYP2D6LMNACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110312933-A1 OXYINDOLE DERIVATIVES WITH MOTILIN RECEPTOR AGONISTIC ACTIVITY RAQUALIA PHARMA INC. (JP) 2011-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110312933-A1 OXYINDOLE DERIVATIVES WITH MOTILIN RECEPTOR AGONISTIC ACTIVITY GPR68, GPR88, GPR52 FDPS 4557/4885MTNR1A 41/4885DRD2 267/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.